NeuroPace

NeuroPace's NAUTILUS study met its primary safety endpoint for the RNS System in treating drug-resistant idiopathic generalized epilepsy, demonstrating a low rate of serious adverse events.

• NeuroPace has submitted three-year safety and effectiveness data from its largest prospective neuromodulation trial, involving over 300 patients with drug-resistant focal epilepsy, to the FDA. • The RNS System stands as the only neuromodulation device offering both stimulation delivery and patient response monitoring capabilities, marking a significant advancement in epilepsy treatment technology. • The study, conducted across more than 30 Level 4 Comprehensive Epilepsy Centers, will continue to track outcomes through a five-year follow-up period as part of the system's FDA approval requirements.

• NeuroPace has submitted three-year safety and effectiveness data from its Post-Approval Study (PAS) of the RNS System to the FDA. • The PAS is the largest prospective study in neuromodulation for drug-resistant focal epilepsy, involving over 300 patients. • The RNS System is the first brain-responsive platform delivering personalized, real-time treatment at the seizure source. • The study will continue to a five-year follow-up, supporting physicians in optimizing care for drug-resistant focal epilepsy patients.

• NeuroPace has submitted three-year safety and effectiveness data to the FDA from its Post-Approval Study (PAS) of the RNS System for drug-resistant focal epilepsy. • The RNS System PAS is the largest prospective post-approval study in neuromodulation, involving over 300 patients with drug-resistant focal epilepsy across multiple centers. • The study evaluates the RNS System's performance in adults with focal epilepsy, the most common form of drug-resistant epilepsy, with a five-year follow-up planned. • The RNS System is the only neuromodulation device that provides stimulation and monitors response, offering a personalized approach to optimize care for patients.

• Rapport Therapeutics receives a Buy rating from JonesTrading, driven by its innovative RAP platform targeting central nervous system disorders. • RAP-219, Rapport's lead candidate, shows promise for treating epilepsy, pain, and bipolar disorder by targeting TARPγ8, with Phase II trials planned for 2025. • Integration of NeuroPace's RNS device could enhance clinical proof of concept for RAP-219, improving patient recruitment and trial outcomes. • Strategic focus on selective targeting aims to minimize side effects, potentially positioning RAP-219 as a best-in-class treatment.